Trial Profile
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid) In Patients With Mantle-Cell Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms RENEW
- Sponsors Celgene Corporation
- 02 Apr 2022 This trial has been completed in France (End Date: 2 March 2011) according to European Clinical Trials Database record.
- 06 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by German Clinical Trials Register.
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003817).